Seeking a Cure for Cancer
Novita is dedicated to developing first-in-class drugs to boost anti-cancer immune responses and to prevent and treat cancer metastasis.
Novita is dedicated to developing first-in-class drugs to prevent and treat cancer metastasis and to boost anti-cancer immune responses.
Seeking a Cure for Cancer
Cancer metastasis is associated with over 90% of cancer related deaths.
A fascin inhibitor would be one of the first drugs to specifically and directly target cancer metastasis.
Science
Novita is developing inhibitors of fascin, a protein involved in cell motility and metastasis, with the aim of targeting the primary cause of over 90% of cancer deaths, for which there is currently no specific drug on the market.
Pre-clinical data demonstrate drug-associated reductions in tumor growth and metastasis, enhanced immune responses and survivals in treated animals, and drug-drug synergism when combined with anti-PD-1 antibodies.
Anti-cancer activity achieved through tandem ability to block tumor metastasis and activate dendritic cells in the tumor microenvironment (TME)
What We've Seen in Cellular Studies
Our data indicate that target-specific anti-fascin agents could have great potential for treating metastatic tumors.
What We've Seen in
Animal Models
Fascin inhibitors have been shown to block migration and invasion of many tumor types and work synergistically with Immuno-oncology agents to increase overall survival in many cancer models.
What We've Seen in Clinical Trials
Phase 1 clinical trial demonstrates that the drug is well tolerated and signals of anti-tumor activity
Phase 2A clinical trials are being conducted at 15 U.S. cancer centers to further evaluate NP-G2-044 as both monotherapy and in combination with anti-PD-1 agents.
Science
Novita is developing inhibitors of fascin, a protein involved in cell motility and metastasis, with the aim of targeting the primary cause of over 90% of cancer deaths, for which there is currently no specific drug on the market.
Pre-clinical data demonstrate drug-associated reductions in tumor growth and metastasis, enhanced immune responses and survivals in treated animals, and drug-drug synergism when combined with anti-PD-1 antibodies.
Anti-cancer activity achieved through tandem ability to block tumor metastasis and activate dendritic cells in the tumor microenvironment (TME)
What We've Seen in Cellular Studies
Our data indicate that target-specific anti-fascin agents could have great potential for treating metastatic tumors.
What We've Seen in
Animal Models
Fascin inhibitors have been shown to block migration and invasion of many tumor types and work synergistically with Immuno-oncology agents to increase overall survival in many cancer models.
What We've Seen in Clinical Trials
Phase 1 clinical trial demonstrates that the drug is well tolerated and generates anti-tumor activity
Phase 2A clinical trials are being conducted at 15 U.S. cancer centers to further evaluate NP-G2-044 as both monotherapy and in combination with anti-PD-1 agents.
About Novita
Novita, a name created to represent “new life”, was founded in 2010 by Drs. Xin-Yun Huang and Jillian Zhang to take their discovery of the novel cancer treatment, fascin inhibitors, from the lab to patients worldwide.
Press Releases
Read our press releases and track the progress of our pharmaceutical research.
October 1st, 2024
Novita Pharmaceuticals Appoints Stewart Campbell as Chief Executive Officer
June 11th, 2024
Novita Pharmaceuticals Appoints Dr. Jose Jimeno as Chief Medical Officer
May 28, 2024
Novita to Present First-in-Class Fascin Inhibitor NP-G2-044 Phase 2 Results in Patients with Advanced and Metastatic Solid Tumors at 2024 ASCO Annual Meeting
Clinical Trials
View our completed and ongoing clinical trials as we continue our fight against cancer.
Posted May 28th, 2024
Phase 2 Clinical Trial of First-in-Class Fascin Inhibitor NP-G2-044 as Monotherapy and in Combination Therapy with anti-PD-1 Immunotherapy in Patients with Advanced Solid Tumor Malignancies
First Posted: August 26th, 2021 | Updated: February 12, 2024
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
First Posted June 27th, 2017 | Updated: December 22, 2020
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
© 2023 Novita Pharmaceuticals, Inc. | Site Design by Digital Elevator